RNA molecule, chimeric NA molecule, double-stranded RNA molecule, and double-stranded chimeric NA molecule
The present invention is directed to provide novel RNA molecules, chimeric NA molecules, double-stranded RNA molecules, and double-stranded chimeric NA molecules. Specifically, an embodiment of the present invention is an RNA molecule for RNA interference to target a mutant allele with a point mutation, in which (1) the molecule has a nucleotide sequence complementary to a nucleotide sequence of a coding region of the mutant allele; and (2) when counted from the base at the 5′-end in a nucleotide sequence complementary to a nucleotide sequence of the mutant allele, (2-1) a base at position 5 or 6 is mismatched to a base in the mutant allele; (2-2) a position 10 or 11 corresponds to the position of the point mutation; and (2-3) a group at the 2′-position of a pentose at positions 6-8 or positions 7 and 8 is modified with, e.g., OCH 3 . In this RNA molecule, one or more ribonucleotides may be replaced by, e.g., a deoxyribonucleotide. The molecule may form a double-stranded RNA with a complementary strand.
1 . An RNA molecule for use in RNA interference to target a mutant allele of a gene, the mutant allele having a point mutation relative to a wild-type allele of the gene, the RNA molecule satisfying the following conditions:
(1) the molecule has a nucleotide sequence complementary to a nucleotide sequence of a coding region of the mutant allele except for a base specified in (2-1) below; and
(2) when counted from the base at the 5′-end in a nucleotide sequence complementary to the nucleotide sequence of the mutant allele,
(2-1) a base at position 5 or 6 is mismatched to a base in the mutant allele;
(2-2) a position 10 or 11 corresponds to the position of the point mutation, and the base at position 10 or 11 is complementary to the base at the position of the point mutation in the mutant allele; and
(2-3) a group at the 2′-position of a pentose in each of ribonucleotides at positions 6-8 or positions 7 and 8 is modified with OCH 3 or fluorine.
2 . The RNA molecule according to claim 1 , wherein, when a base at the 5′-end of the nucleotide sequence specified in (1) of claim 1 is cytosine or guanine, it is replaced by adenine or uracil.
3 . The RNA molecule according to claim 1 , wherein, when a base at the 3′-end of the nucleotide sequence specified in (1) of claim 1 is adenine or uracil, it is replaced by cytosine or guanine.
4 . The RNA molecule according to claim 1 , wherein the RNA molecule comprises 13-28 nucleotides.
5 . The RNA molecule according to claim 1 , further comprising 1-3 nucleotide(s) at the 3′-end of the nucleotide sequence specified in (1) of claim 1 .
6 . A chimeric NA molecule, wherein one or more ribonucleotides in an RNA molecule according to claim 1 are replaced by a deoxyribonucleotide, an artificial nucleic acid, or a nucleic acid analog.
7 . A double-stranded RNA molecule comprising a guide strand and a passenger strand, the guide strand being an RNA molecule according to claim 1 , and the passenger strand being an RNA molecule with a sequence complementary to that of the RNA molecule of the guide strand.
8 . The double-stranded RNA molecule according to claim 7 , wherein the RNA molecule comprises an overhang at the 3′-end of the guide strand and/or an overhang at the 3′-end of the passenger strand.
9 . The double-stranded RNA molecule according to claim 8 , wherein the overhang(s) comprise 1-3 nucleotides.
10 . A double-stranded chimeric NA molecule, wherein one or more ribonucleotides in a double-stranded RNA molecule according to claim 7 is by a deoxyribonucleotide, an artificial nucleic acid, or a nucleic acid analog.
11 . A method for producing the RNA molecule according to claim 1 , comprising making a RNA molecule having a nucleotide sequence complementary to a nucleotide sequence of a coding region of a mutant allele of a gene, wherein the mutant allele has a point mutation relative to a wild-type allele of the gene, except the method comprises making the RNA molecule sequence have a base at position 5 or 6 that is mismatched to a base in the mutant allele from the 5′-end of the RNA molecule sequence; and
further comprising making position 10 or 11 from the 5′-end of the RNA molecule sequence correspond to the position of the point mutation, and the base at position 10 or 11 complementary to the base at the position of the point mutation in the mutant allele, and a group at the 2′-position of a pentose in each of ribonucleotides at positions 6-8 or positions 7 and 8 modified with OCH 3 or fluorine.
12 . A method for producing the chimeric NA molecule according to claim 6 , comprising making a RNA molecule having a nucleotide sequence complementary to a nucleotide sequence of a coding region of a mutant allele of a gene, wherein the mutant allele has a point mutation relative to a wild-type allele of the gene, except the method comprises making the RNA molecule sequence have a base at position 5 or 6 that is mismatched to a base in the mutant allele from the 5′-end of the RNA molecule sequence;
further comprising making position 10 or 11 from the 5′-end of the RNA molecule sequence correspond to the position of the point mutation, and the base at position 10 or 11 complementary to the base at the position of the point mutation in the mutant allele, and a group at the 2′-position of a pentose in each of ribonucleotides at positions 6-8 or positions 7 and 8 modified with OCH 3 or fluorine; and
wherein one or more ribonucleotides in the RNA molecule are replaced with a deoxyribonucleotide, an artificial nucleic acid, or a nucleic acid analog.
13 . A method for performing RNA interference in a cell containing a wild-type allele of a gene and a mutant allele of the gene, by targeting the mutant allele with an RNA molecule, the mutant allele having a point mutation, wherein the method comprises the step of:
introducing the RNA molecule according to claim 1 into the cell.